Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
These effects occurred in 4070% of treated patients in clinical trials
Lys(9) for Glu(9) substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(936)amide and exendin (939)
Grieger JA, Grzeskowiak LE, Wilson RL, et al
Re de leeuw SP, et al
(Lausanne) 12, 689678
She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Bayer, Eli Lilly, Novo Nordisk, Travere Therapeutics Inc, ProKidney and Alnylam
US$ 28.38
US$ 24.21
US$ 25.75
US$ 20.26
US$ 27.88
US$ 25.41
US$ 28.12
US$ 26.78
US$ 21.16
